Posttranslational modification impact on the mechanism by which amyloid‐β induces synaptic dysfunction
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Oligomeric amyloid‐β (Aβ) 1‐42 disrupts synaptic function at an early stage of Alzheimer's disease ( AD ). Multiple posttranslational modifications of Aβ have been identified, among which N‐terminally truncated forms are the most abundant. It is not clear, however, whether modified species can induce synaptic dysfunction on their own and how altered biochemical properties can contribute to the synaptotoxic mechanisms. Here, we show that a prominent isoform, pyroglutamated Aβ3( pE )‐42, induces synaptic dysfunction to a similar extent like Aβ1‐42 but by clearly different mechanisms. In contrast to Aβ1‐42, Aβ3( pE )‐42 does not directly associate with synaptic membranes or the prion protein but is instead taken up by astrocytes and potently induces glial release of the proinflammatory cytokine TNF α. Moreover, Aβ3( pE )‐42‐induced synaptic dysfunction is not related to NMDAR signalling and Aβ3( pE )‐42‐induced impairment of synaptic plasticity cannot be rescued by D1‐agonists. Collectively, the data point to a scenario where neuroinflammatory processes together with direct synaptotoxic effects are caused by posttranslational modification of soluble oligomeric Aβ and contribute synergistically to the onset of synaptic dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 3×
“In particular, TNF a was shown to influence A b production, increase oligomer-induced apoptosis and mediate A b - induced long-term potentiation (LTP) [28].”
InfluentialThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 3×
“Numerous studies indicate that soluble A b oligomers play a key role in the onset of synaptic dysfunction in early stage AD [1,2].”
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“The 5XFAD (+/ ) animals [62] were kind gift from Prof.”
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“In addition, evidence was provided that astrocytes have a potential role in internalisation and degradation of A b [56,57] as well as they are a main source of ApoE whose polymorphism ( e -4 version) is the main genetic risk factor in AD [58].”
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 2×
“Numerous cytokines such as TNF a , IL-1 b or IL-6 were reported to be upregulated in AD brain and could potentially aggravate disease progression [27 – 29].”
Synaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 1×
“Stimulation of synaptic NMDAR induces the expression of cell survival and plasticity genes, while their extrasynaptic counterparts primarily drive the expression of cell death genes, linking the latter pathway to disease [30,31].”
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468 · cited 1×
“It was also reported that Ab1-42 clusters mGlu5 [20] and might displace NMDAR from synaptic sites, in a manner that might involve a cis-interaction between the GluN1 subunit of NMDAR and mGlu5 [43].”
Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J., & Anwyl, R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1633-03.2004 · Cited by 437
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427
Self-citationHe, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Kimura, R., & Ohno, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.006 · Cited by 333
Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain
Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., & Kawashima, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12970-0 · Cited by 270
On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro)
Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Böhm, G., & Demuth, H.-U. (2006) · Biochemistry · doi:10.1021/bi0612667 · Cited by 254 · cited 1×
“A b 3(pE)-42 exhibits distinct structural features that might carry specific neurotoxic activity [9,11,13 – 15].”
Self-citationPyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides
Schlenzig, D., Manhart, S., Cinar, Y., Kleinschmidt, M., Hause, G., Willbold, D., Funke, S. A., Schilling, S., & Demuth, H.-U. (2009) · Biochemistry · doi:10.1021/bi900818a · Cited by 228
Self-citationHarigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202
New developments on the role of NMDA receptors in Alzheimer's disease
Malinow, R. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.09.001 · Cited by 132
Alexandru, A., Jagla, W., Graubner, S., Becker, A., Bäuscher, C., Kohlmann, S., Sedlmeier, R., Raber, K. A., Cynis, H., Rönicke, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-11.2011 · Cited by 102
Self-citationChen, X., Lin, R., Chang, L., Xu, S., Wei, X., Zhang, J., Wang, C., Anwyl, R., & Wang, Q. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.054 · Cited by 93 · cited 2×
“TNFa was identified as the principle neurotoxic agent resulting from Ab-induced proinflammatory transcriptional changes [27,44,52,55].”
Jürgensen, S., Antonio, L. L., Mussi, G. E. A., Brito-Moreira, J., Bomfim, T. R., De Felice, F. G., Garrido-Sanabria, E. R., Cavalheiro, É. A., & Ferreira, S. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177790 · Cited by 88 · cited 1×
“In previous studies, it was shown that administration of dopamine D1/D5 receptor agonists prevents the LTP impairment induced by conventional Ab1-42 [39,41].”
Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains
Hosoda, R., Saido, T. C., Otvos, L., Arai, T., Mann, D. M. A., Lee, V. M.-Y., Trojanowski, J. Q., & Iwatsubo, T. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199811000-00012 · Cited by 79
Cited by
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
“In contrast, Ca 2 + entry through GluN2B-containing NMDARs, which are expressed extrasynaptically, triggers the CREB shut-off pathway (Leveille et al., 2008).”
BackgroundInfluentialSengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0431-6 · Cited by 129
Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005807 · Cited by 115
Metadata
- Authors
- Grochowska, K. M., Yuanxiang, P., Bär, J., Raman, R., Brugal, G., Sahu, G., Schweizer, M., Bikbaev, A., Schilling, S., Demuth, H., & Kreutz, M. R.
- Venue
- EMBO reports
- Published
- 2017-04-18
- Volume
- 18
- Issue
- 6
- Pages
- 962-981
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2606113932
- Cited by
- 73
- References
- 26
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.